


THAT WHICH IS CLAIMED:


1. A compound of formula (I):




wherein:

R₁ and R₂ can be the same or different and are each independently selected from one or more of the following and combinations thereof:


(a) -OR₃, wherein R₃ is H or C₁-C₆ straight-chain or branched unsubstituted or substituted alkyl;




is C₁-C₆ straight-chain or branched unsubstituted or substituted alkyl or -OR₅, wherein R₅ is C₁-C₆ straight-chain or branched unsubstituted or substituted alkyl;







is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20; and R₆ is C₁-C₆ straight-chain or branched unsubstituted or substituted alkyl;



(i) -C(=O)-O-R₈, wherein R₈ is C₁-C₆ straight-chain or branched unsubstituted or substituted alkyl;













R₁₂ are each independently H or a protecting group; and R₁₃ is C₁-C₆ straight-chain or branched unsubstituted or substituted alkyl;









provided that R₁ and R₂ cannot both be –OH or both be –OR₃ at the same time; and pharmaceutically acceptable salts thereof.

2. The compound of claim 1, wherein:










(f) R₁ is , wherein R₇ is -C(=O)-O-R₈ and R₂ is selected

from $-\text{OR}_3$, $\left(\text{OCH}_2\text{O} \right)_n \text{C}(=\text{O})\text{R}_4$, $\left(\text{OCH}_2\text{CH}_2 \right)_m \left(\text{OCH}_2\text{CH}_2\text{O} \right)_p \text{R}_6$, $\left(\text{OCH}_2\text{CH}_2\text{O} \right)_q \text{C}(=\text{O})\text{R}_{19}$, $\left(\text{OCH}_2\text{CH}_2\text{O} \right)_r \text{C}(=\text{O})\text{R}_{20}$, $\left(\text{OCH}_2\text{CH}_2\text{O} \right)_s \text{C}(=\text{O})\text{R}_{21}$, and $\left(\text{OCH}_2\text{CH}_2\text{O} \right)_t \text{C}(=\text{O})\text{R}_7$, wherein R_7 is selected from $-\text{C}(=\text{O})-\text{O}-\text{R}_8$,

(g) R_1 is , wherein R_7 is  and R_2

is selected from $-\text{OR}_3$, $(-\text{O}-\text{CH}_2-\text{O}-\text{C}(=\text{O})-\text{R}_4)_n$, $(-\text{O}-\text{CH}_2-\text{CH}_2)_m(-\text{O}-\text{CH}_2-\text{CH}_2-\text{R}_6)_p$, $(-\text{O}-\text{CH}_2-\text{C}(\text{R}_{19})=\text{C}(\text{O})-\text{O}-\text{C}(=\text{O})-\text{O}-\text{CH}_2-\text{O}-)_q$, $(-\text{N}(\text{R}_{20})-\text{CH}(\text{C}(=\text{O})-\text{R}_{21})-\text{CH}_2)_u$, $(-\text{O}-\text{C}_6\text{H}_4-\text{R}_7)_v$, wherein R_7 is selected from $-\text{C}(=\text{O})-\text{O}-\text{R}_8$, $(-\text{CH}_2-\text{CH}(\text{N}(\text{R}_{12})\text{R}_{11})-\text{C}(=\text{O})-\text{NR}_9)_w$, $(-\text{CH}_2-\text{CH}(\text{C}(=\text{O})-\text{NR}_{11}\text{R}_{12})-\text{CH}_2)_x$, $(-\text{CH}_2-\text{CH}(\text{N}(\text{R}_{15})\text{R}_{14})-\text{C}(=\text{O})-\text{NR}_{16}\text{R}_{17})_y$, and $(-\text{CH}_2-\text{CH}(\text{N}(\text{R}_{12})\text{R}_{11})-\text{C}(=\text{O})-\text{NR}_9)_z$; and







provided that R_1 and R_2 cannot both be ---OH or both be ---OR_3 at the same time; and pharmaceutically acceptable salts thereof.







3. The compound of claim 1, wherein:





(a-i) R_1 is ---OH and R_2 is selected from:



(a-ii) R_1 is ---OR_3 and R_2 is selected from:







4. The compound of any of claims 1-3, wherein R₃, R₄, R₅, R₆, R₈, R₉, R₁₀, R₁₃, R₁₅, and R₂₂ are each independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, t-butyl, pentyl, isopentyl, neopentyl, n-hexyl, 2-methylpentane, 3-methylpentane, 2,2-dimethylbutane, and 2,3-dimethylbutane.


5. The compound of any of claims 1-4, wherein R₉, R₁₄, R₁₆, R₁₇, R₁₉, R₂₀, R₂₃, and R₂₄ are each independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, and t-butyl.

6. The compound of any of claims 1-5, wherein the protecting group is selected from tert-butoxycarbonyl (boc), carbobenzyloxy (Cbz), p-Methoxybenzyl carbonyl (Moz or MeOZ), 9-fluorenylmethyloxycarbonyl (Fmoc) group, benzyl (Bn), p-methoxybenzyl (PMB), 3,4-dimethoxybenzyl (DMPM), tosyl (Ts), Troc (trichloroethyl chloroformate), (4-nitrophenyl)sulfonyl (Nosyl), and nitrophenylsulfonyl (Nps).


7. The compound of any of claim 1-6, wherein R_{18} is selected from phenyl.








8. The compound of any of claims 1-7, wherein:



(a-i) R_1 is $-OH$ and R_2 is selected from:





(a-ii) R_1 is selected from $-OCH_3$, $-OCH(CH_3)_2$, and $-OC(CH_3)_3$ and R_2 is selected from:








(h) R₁ is  or  and R₂ is -OCH₃ (18, 20); and

(i) R₁ is  or  and R₂ is -OCH₃ (3, 4).

9. The compound of any of claims 1-8, wherein the compound of formula (I) is selected from:







10. A pharmaceutical composition comprising a compound of any of claims 1-9 and a pharmaceutically acceptable excipient.

11. A method for treating a disease, disorder, or condition associated with inflammation, the method comprising administering to a subject in need of treatment thereof a compound of any of claims 1-9 or a composition of claim 10.